CN110036024B - 肌肉性能改善化合物 - Google Patents

肌肉性能改善化合物 Download PDF

Info

Publication number
CN110036024B
CN110036024B CN201780073720.2A CN201780073720A CN110036024B CN 110036024 B CN110036024 B CN 110036024B CN 201780073720 A CN201780073720 A CN 201780073720A CN 110036024 B CN110036024 B CN 110036024B
Authority
CN
China
Prior art keywords
leu
val
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780073720.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110036024A (zh
Inventor
J·W·弗里杰布勒德
M·M·博伊多
O·布登克
R·斯凯利诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmafox Therapeutics AG
Original Assignee
Pharmafox Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics AG filed Critical Pharmafox Therapeutics AG
Publication of CN110036024A publication Critical patent/CN110036024A/zh
Application granted granted Critical
Publication of CN110036024B publication Critical patent/CN110036024B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780073720.2A 2016-11-29 2017-11-28 肌肉性能改善化合物 Active CN110036024B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1620119.6 2016-11-29
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (2)

Publication Number Publication Date
CN110036024A CN110036024A (zh) 2019-07-19
CN110036024B true CN110036024B (zh) 2024-05-07

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780073720.2A Active CN110036024B (zh) 2016-11-29 2017-11-28 肌肉性能改善化合物

Country Status (11)

Country Link
US (1) US11407799B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7683901B2 (cg-RX-API-DMAC7.html)
KR (1) KR102622245B1 (cg-RX-API-DMAC7.html)
CN (1) CN110036024B (cg-RX-API-DMAC7.html)
AU (1) AU2017367277B2 (cg-RX-API-DMAC7.html)
CA (1) CA3045245A1 (cg-RX-API-DMAC7.html)
GB (1) GB201620119D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ754625A (cg-RX-API-DMAC7.html)
WO (1) WO2018100483A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903261B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN120535607A (zh) 2018-01-12 2025-08-26 科乐斯疗法公司 激活素受体iib型变体及其使用方法
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2023512423A (ja) * 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
EP4121090A4 (en) * 2020-03-20 2024-09-04 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
EP4121088A4 (en) * 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4185316A4 (en) * 2020-07-24 2024-07-17 Agency for Science, Technology and Research WOUND HEALING COMPOSITION AND USES THEREOF
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
KR20230169123A (ko) * 2021-03-10 2023-12-15 악셀레론 파마 인코포레이티드 Actrii-alk4 길항제 및 심부전을 치료하는 방법
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481339A (zh) * 2009-09-04 2012-05-30 纽罗图恩股份公司 用作药物的能够恢复肌肉强度的修饰的聚集蛋白片段

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503673A (ja) * 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP2056850A4 (en) 2006-08-08 2011-10-12 Univ Louisiana State THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN
BRPI0716249A2 (pt) * 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
HUE035240T2 (hu) * 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8710016B2 (en) * 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481339A (zh) * 2009-09-04 2012-05-30 纽罗图恩股份公司 用作药物的能够恢复肌肉强度的修饰的聚集蛋白片段

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biomarkers in sarcopenia_ A multifactorial approach;Curcio等;《Experimental Gerontology》;20160912;第85卷;第1-8页 *

Also Published As

Publication number Publication date
KR20190085132A (ko) 2019-07-17
AU2017367277B2 (en) 2021-04-01
CN110036024A (zh) 2019-07-19
JP2023116479A (ja) 2023-08-22
US11407799B2 (en) 2022-08-09
WO2018100483A1 (en) 2018-06-07
JP7683901B2 (ja) 2025-05-27
AU2017367277A1 (en) 2019-07-04
EP3548509A1 (en) 2019-10-09
KR102622245B1 (ko) 2024-01-05
ZA201903261B (en) 2020-02-26
CA3045245A1 (en) 2018-06-07
US20210253654A1 (en) 2021-08-19
NZ754625A (en) 2023-03-31
GB201620119D0 (en) 2017-01-11
JP2019536818A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
CN110036024B (zh) 肌肉性能改善化合物
CN111727203B (zh) Wnt替代分子和其用途
TWI633117B (zh) 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
JP2021143207A (ja) 熱発生性脂肪細胞を増加させるための方法
JP2022044589A (ja) ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用
JP6267425B2 (ja) 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
CN101687927B (zh) 针对g蛋白偶联的受体（gpcr）的抗体
KR101844596B1 (ko) 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
JPH08502170A (ja) ノッチタンパク質および核酸に基づいた治療および診断方法ならびに組成物
JP2014506568A (ja) Ｗｎｔ組成物およびその使用方法
JP2021502378A (ja) アクチビンＩＩａ型受容体変異体およびそれらの使用方法
JP2017513921A (ja) ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
JP2014502965A (ja) ｕＰＡＲアンタゴニストおよびその使用
US7575751B2 (en) Activin-A mutants
DK2744831T3 (en) TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME
ES2259458T3 (es) Persefina humana.
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
WO2005017151A1 (ja) アポトーシスを誘導するip3受容体タンパク質の末端切断型変異体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment